ConductScience.org, home

Paper36979809

A Brief Review of Duchenne Muscular Dystrophy Treatment Options, with an Emphasis on Two Novel Strategies.

Heydemann A and 1 other. Biomedicines, 2023. Cited by 22 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. A Brief Review of Duchenne Muscular Dystrophy Treatment Options, with an Emphasis on Two Novel Strategies. Papers, record 36979809. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36979809

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A Brief Review of Duchenne Muscular Dystrophy Treatment Options, with an Emphasis on Two Novel Strategies.
PubMed
Journal
Biomedicines
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
22
iCite
Relative citation ratio, by iCite
3.08
iCite
Revised in PubMed
2023-03-31
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Heydemann AAhlkehttps://orcid.org/0000-0002-2626-3787
2Siemionow MMaria

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References100

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132,946,430Stem cell therapy for muscular dystrophies.J Clin Invest2020https://conductscience.org/library/papers/32946430PubMed
228,391,962SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy.Mol Ther2017https://conductscience.org/library/papers/28391962PubMed
318,444,914Hematopoietic stem cell engraftment and seeding permits multi-lymphoid chimerism in vascularized bone marrow transplants.Am J Transplant2008https://conductscience.org/library/papers/18444914PubMed
422,068,425Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector.Mol Ther2012https://conductscience.org/library/papers/22068425PubMed
51,483,043The dystrophin-related protein, utrophin, is expressed on the sarcolemma of regenerating human skeletal muscle fibres in dystrophies and inflammatory myopathies.Neuromuscul Disord1992https://conductscience.org/library/papers/1483043PubMed
615,806,097Highly efficient endogenous human gene correction using designed zinc-finger nucleases.Nature2005https://conductscience.org/library/papers/15806097PubMed
719,933,107Breaking the code of DNA binding specificity of TAL-type III effectors.Science2009https://conductscience.org/library/papers/19933107PubMed
833,669,654Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies.Pharmaceutics2021https://conductscience.org/library/papers/33669654PubMed
926,417,069A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy.Proc Natl Acad Sci U S A2015https://conductscience.org/library/papers/26417069PubMed
1031,039,133Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy.JCI Insight2019https://conductscience.org/library/papers/31039133PubMed
1135,634,851Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy.J Neuromuscul Dis2022https://conductscience.org/library/papers/35634851PubMed
1231,664,444Effect of Combination l-Citrulline and Metformin Treatment on Motor Function in Patients With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.JAMA Netw Open2019https://conductscience.org/library/papers/31664444PubMed
1329,705,868New Hope for Treatment of Duchene Dystrophy by Employing Dystrophin Expressing Chimeric Cells - Studies Published in Stem Cell Reviews and Reports.Stem Cell Rev Rep2018https://conductscience.org/library/papers/29705868PubMed
1435,221,289Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.Drug Metab Dispos2022https://conductscience.org/library/papers/35221289PubMed
1531,789,220Muscular dystrophies.Lancet2019https://conductscience.org/library/papers/31789220PubMed
1629,203,355A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy.Neuromuscul Disord2018https://conductscience.org/library/papers/29203355PubMed
1734,592,975Long term treatment with ataluren-the Swedish experience.BMC Musculoskelet Disord2021https://conductscience.org/library/papers/34592975PubMed
1823,473,647Duchenne muscular dystrophy drug discovery - the application of utrophin promoter activation screening.Expert Opin Drug Discov2013https://conductscience.org/library/papers/23473647PubMed
1918,006,908Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point.Cancer Epidemiol Biomarkers Prev2007https://conductscience.org/library/papers/18006908PubMed
2032,539,076Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial.JAMA Neurol2020https://conductscience.org/library/papers/32539076PubMed

See all 100 references

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.

PMIDTitleJournalYearIn PapersSource
42,703,430A Registry-Based Perspective of Interventional Clinical Trials for Duchenne Muscular Dystrophy.Cureus2026https://conductscience.org/library/papers/42703430PubMed
42,251,435Bacteroides-derived endocannabinoid-like commendamide attenuates skeletal muscle ferroptosis in vitro: implications for Duchenne muscular dystrophy.J Transl Med2026https://conductscience.org/library/papers/42251435PubMed
42,096,741Generation of an induced pluripotent stem cell line (NCHi026-A) from a patient with a partial deletion of exon 55 in the DMD gene.Stem Cell Res2026https://conductscience.org/library/papers/42096741PubMed
41,961,170Estimating health-state utility values for family-caregivers of patients with Duchenne muscular dystrophy using time trade-off valuation.J Patient Rep Outcomes2026https://conductscience.org/library/papers/41961170PubMed
41,466,293Assessing rare disease understanding: a novel disease readiness level framework.Orphanet J Rare Dis2025https://conductscience.org/library/papers/41466293PubMed
41,410,800Long-Term Safety and Efficacy of Systemic DT-DEC01 Cell Therapy in Non-Ambulatory Duchenne Muscular Dystrophy Patients: a 24-Month Clinical Evaluation.Stem Cell Rev Rep2026https://conductscience.org/library/papers/41410800PubMed
41,307,959Proteomics-based evaluation of AAV dystrophin gene therapy outcomes in mdx skeletal muscle.JCI Insight2026https://conductscience.org/library/papers/41307959PubMed
40,869,293Integrative Approaches to Myopathies and Muscular Dystrophies: Molecular Mechanisms, Diagnostics, and Future Therapies.Int J Mol Sci2025https://conductscience.org/library/papers/40869293PubMed
40,195,304The SIRT1 activator SRT2104 exerts exercise mimetic effects and promotes Duchenne muscular dystrophy recovery.Cell Death Dis2025https://conductscience.org/library/papers/40195304PubMed
40,150,443The Uneven Effect of Rare Diseases on Functional Status and Work Capacity.Healthcare (Basel)2025https://conductscience.org/library/papers/40150443PubMed
39,778,566Safety and Tolerability of Wharton's Jelly-Derived Mesenchymal Stem Cells for Patients With Duchenne Muscular Dystrophy: A Phase 1 Clinical Study.J Clin Neurol2025https://conductscience.org/library/papers/39778566PubMed
39,337,654The Effects of Growth Hormone Treatment Beyond Growth Promotion in Patients with Genetic Syndromes: A Systematic Review of the Literature.Int J Mol Sci2024https://conductscience.org/library/papers/39337654PubMed
39,017,908Chimeric Cell Therapy Transfers Healthy Donor Mitochondria in Duchenne Muscular Dystrophy.Stem Cell Rev Rep2024https://conductscience.org/library/papers/39017908PubMed
38,501,170Cross-species modeling of muscular dystrophy in Caenorhabditis elegans using patient-derived extracellular vesicles.Dis Model Mech2024https://conductscience.org/library/papers/38501170PubMed
37,999,748Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration.Arch Immunol Ther Exp (Warsz)2023https://conductscience.org/library/papers/37999748PubMed
37,991,502mCherry on Top: A Positive Read-Out Cellular Platform for Screening DMD Exon Skipping Xenopeptide-PMO Conjugates.Bioconjug Chem2023https://conductscience.org/library/papers/37991502PubMed
37,707,670Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration.Stem Cell Rev Rep2023https://conductscience.org/library/papers/37707670PubMed

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
DMD1,756PubTator's text mininghttps://conductscience.org/library/genes/1756NCBI Gene
ESR12,099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene
ITGA73,679PubTator's text mininghttps://conductscience.org/library/genes/3679NCBI Gene
PPARGC1A10,891PubTator's text mininghttps://conductscience.org/library/genes/10891NCBI Gene
UTRN7,402PubTator's text mininghttps://conductscience.org/library/genes/7402NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36979809

GET https://conductscience.org/api/papers/v1/36979809/references?page=2